| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/29/2010 | WO2010084050A2 Quinazolinone derivatives useful as vanilloid antagonists |
| 07/29/2010 | WO2010084041A2 Pharmaceutical compositions with superior product performance and patient compliance |
| 07/29/2010 | WO2010083975A1 Combinations comprising methotrexate and dhodh inhibitors |
| 07/29/2010 | WO2010083894A1 Abuse resistant melt extruded formulation having reduced alcohol interaction |
| 07/29/2010 | WO2010083870A1 Novel heterocyclic compounds for use as metap-2 inhibitors |
| 07/29/2010 | WO2010083843A1 Controlled release formulations with continuous efficacy |
| 07/29/2010 | WO2010083752A1 High-purity febuxostat and the method for preparation |
| 07/29/2010 | WO2010083725A1 Cephalosporin derivatives containing substituted nitrogen-containing fused heterocyclic ring |
| 07/29/2010 | WO2010083720A1 Optical pure quinazoline compounds |
| 07/29/2010 | WO2010083649A1 Bisarylurea derivatives and their use |
| 07/29/2010 | WO2010083645A1 PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF |
| 07/29/2010 | WO2010083633A1 Compounds uesed for anti-hypertension, preparation methods, compositions and uses thereof |
| 07/29/2010 | WO2010083617A1 Pyrazolopyrimidines as protein kinase inhibitors |
| 07/29/2010 | WO2010083615A1 Compositions and methods for silencing apolipoprotein c-iii expression |
| 07/29/2010 | WO2010083613A1 Phosphate management with small molecules |
| 07/29/2010 | WO2010083589A1 Biofilm-removing antimicrobial compositions and uses thereof |
| 07/29/2010 | WO2010083582A1 Use of deferiprone for treatment and prevention of iron-related eye disorders |
| 07/29/2010 | WO2010083570A1 Novel metabolic disease therapy |
| 07/29/2010 | WO2010065923A3 Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| 07/29/2010 | WO2010065802A3 Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds |
| 07/29/2010 | WO2010065799A3 Amine substituted piperidine melanocortin receptor-specific compounds |
| 07/29/2010 | WO2010065512A3 Compounds for treating proliferative disorders |
| 07/29/2010 | WO2010064958A3 Protein kinase c inhibitors exhibiting an anti-inflammatory, anti-allergic and anti-asthma effect |
| 07/29/2010 | WO2010064252A3 Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents |
| 07/29/2010 | WO2010063948A3 Novel c-xyloside oxime compounds, and cosmetic use |
| 07/29/2010 | WO2010060941A3 Contrast agents |
| 07/29/2010 | WO2010060037A3 Adamantane modulators of nmda receptor and/or 5ht3 receptor |
| 07/29/2010 | WO2010059529A3 Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection |
| 07/29/2010 | WO2010056877A3 Haloalkyl containing compounds as cysteine protease inhibitors |
| 07/29/2010 | WO2010056872A3 Antimicrobial compositions |
| 07/29/2010 | WO2010056039A3 Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability |
| 07/29/2010 | WO2010055148A3 Dosage of oligonucleotides suitable for the treatment of tumors |
| 07/29/2010 | WO2010051291A8 Besifloxacin ophthalmic composition for the treatment or control of infection |
| 07/29/2010 | WO2010049946A3 Thyroid receptor ligands |
| 07/29/2010 | WO2010048164A3 N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints |
| 07/29/2010 | WO2010047559A3 Sustained-release pharmaceutical formulations |
| 07/29/2010 | WO2010045656A3 Novel sglt2 inhibitor dosage forms |
| 07/29/2010 | WO2010045615A3 Treatment of organophosphate exposure with ocinaplon |
| 07/29/2010 | WO2010045582A3 Compositions and methods for treating or preventing hypoxic or ischemic injury |
| 07/29/2010 | WO2010045417A3 Combination therapies for the treatment of obesity |
| 07/29/2010 | WO2010045416A3 Combination therapies for the treatment of obesity |
| 07/29/2010 | WO2010045212A3 Nicotinic acetylcholine receptor ligands and the uses thereof |
| 07/29/2010 | WO2010044585A3 Piperidine compounds, pharmaceutical composition comprising the same and its use |
| 07/29/2010 | WO2010043717A3 Pharmaceutical topical compositions |
| 07/29/2010 | WO2010042925A3 Compositions and methods for treating alcohol use disorders, pain and other diseases |
| 07/29/2010 | WO2010042652A3 Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| 07/29/2010 | WO2010042633A3 Naringenin complexes and methods of use thereof |
| 07/29/2010 | WO2010041140A3 Treatment of proliferative disorders with a death receptor agonist |
| 07/29/2010 | WO2010041138A3 Complex between human insulin and an amphiphilic polymer, and use of said complex for preparing a quick human insulin formulation |
| 07/29/2010 | WO2010039920A3 Boldine compounds for promoting bone growth |
| 07/29/2010 | WO2010039641A3 Long term drug delivery devices with polyurethane-based polymers and their manufacture |
| 07/29/2010 | WO2010039545A3 1,2-benzisothiazolinone and isoindolinone derivatives |
| 07/29/2010 | WO2010033236A3 Methods and compositions for treating bacterial infections by inhibiting quorum sensing |
| 07/29/2010 | WO2010023689A3 Microparticles |
| 07/29/2010 | WO2010022238A9 Anti-flavivirus therapeutic |
| 07/29/2010 | WO2010018549A3 Therapeutic compositions containing macitentan |
| 07/29/2010 | WO2010014930A3 Piperidine derivatives as jak3 inhibitors |
| 07/29/2010 | WO2010007181A3 New salt forms of an aminoindan derivative |
| 07/29/2010 | WO2010006697A3 Powders for reconstitution |
| 07/29/2010 | WO2010006238A3 Stimulus-responsive apta-chelamers |
| 07/29/2010 | WO2010005529A3 Once-a-day rna-polymerase inhibiting and elongation factor g (ef-g) inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant staphylococcus aureus |
| 07/29/2010 | WO2010003647A3 Artificial oxygen carriers and use thereof |
| 07/29/2010 | WO2010002940A3 Heterogeneous synthesis of multivalent chimeric immunomodulatory compounds using platform based molecules |
| 07/29/2010 | WO2009158467A3 Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors |
| 07/29/2010 | WO2009157018A3 Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
| 07/29/2010 | WO2009156724A3 Pyrido-indole-carboxylic acid compounds |
| 07/29/2010 | WO2009153457A3 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action |
| 07/29/2010 | WO2009143347A9 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
| 07/29/2010 | WO2009142594A9 The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders |
| 07/29/2010 | WO2009089632A8 Implantable devices for promoting reendothelialization and methods of use thereof |
| 07/29/2010 | WO2009082701A8 Hcv protease inhibitors and uses thereof |
| 07/29/2010 | WO2009068482A8 Amino triazoles as pi3k inhibitors |
| 07/29/2010 | WO2009035159A8 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor |
| 07/29/2010 | WO2006013193A8 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors |
| 07/29/2010 | US20100192240 Regulation of expression of pi3kbeta protein in tumors |
| 07/29/2010 | US20100191325 Coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer |
| 07/29/2010 | US20100190977 4-phenylamino-quinazolin-6-yl-amides |
| 07/29/2010 | US20100190933 Multi-arm polymer prodrugs |
| 07/29/2010 | US20100190867 Stable and bioavailable compositions of isomers of lycopene for skin and hair |
| 07/29/2010 | US20100190862 Composition for treating atopic dermatitis comprising hirsutenone as an active ingredient |
| 07/29/2010 | US20100190861 Cycloalkylamines as monoamine reuptake inhibitors |
| 07/29/2010 | US20100190860 Methods for selectively enhancing antinociceptive potency of local anesthetics |
| 07/29/2010 | US20100190859 Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis |
| 07/29/2010 | US20100190858 Pharmaceutical Formulations Containing Lipoic Acid Derivatives |
| 07/29/2010 | US20100190857 Lipid-improving agent and composition containing lipid-improving agent |
| 07/29/2010 | US20100190856 Novel Polyhydroxylated Compounds as Fatty Acid Synthase (FASN) Inhibitors |
| 07/29/2010 | US20100190855 Organic compounds |
| 07/29/2010 | US20100190854 Composition and method to treat mastitis |
| 07/29/2010 | US20100190853 Topical application of travoprost for combating hair loss |
| 07/29/2010 | US20100190852 Short acting phenylalkylamine calcium channel blockers and uses thereof |
| 07/29/2010 | US20100190851 Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions |
| 07/29/2010 | US20100190850 Water-soluble binuclear nitrosyl iron complexes with natural aliphatic thiolyls possessing cytotoxic, apoptotic and no-donor activity |
| 07/29/2010 | US20100190848 Cysteine-protease inhibitors |
| 07/29/2010 | US20100190847 Oral composition with an antiageing effect on the skin |
| 07/29/2010 | US20100190845 Method of treating cancer using atp synthase inhibitors |
| 07/29/2010 | US20100190844 Process for preparation of aglucone isoflavones |
| 07/29/2010 | US20100190843 Tubulin Isotype Screening in Cancer Therapy Using Halichondrin B Analogs |
| 07/29/2010 | US20100190842 Influenza polynucleotides, expression constructs, compositions, and methods of use |
| 07/29/2010 | US20100190841 Genetic suppression and replacement |
| 07/29/2010 | US20100190840 Tissue specific gene therapy treatment |